A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients With Age-Related Macular Degeneration
Phase: PHASE2
Conditions: Age-related Macular Degeneration
Sponsor: Senju Pharmaceutical Co., Ltd.

 
 
 
NCT Number: NCT03869684 
 
 
Protocol Number: MT-0814/2-01 
 
 
Study Title: 
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-
Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the 
Treatment of Patients with Age-Related Macular Degeneration 
 
 
Protocol Version: Version 4.0: 29 November 2019